The Week in Review: September 29 – October 6, 2017

Friday, October 6, 2017 News Recap: Liver Cancer Two studies on liver cancer in the news last week highlighted the global prevalence and causes of this terrible disease.  The first showed a direct correlation between excess weight and cancer occurrence (including liver cancer) – Cancers linked to excess weight make up 40% of all US diagnoses, study finds, while the second focussed on the global incidence of primary liver cancer. Hepatitis B virus wa...

Reactivation Rate of Hepatitis B in Inflammatory Arthritis Tx With DMARDs

It's not only DAAs than can reactivate HBV. In patients with inflammatory arthritis receiving disease-modifying antirheumatic drugs (DMARDs), rates of hepatitis B (HBV) reactivation differ between those whose disease is resolved and those with chronic HBV infection. Findings from the systematic review and meta-analysis were published in Arthritis Care & Research (Hoboken). Patients with chronic HBV generally have a 5-fold to 8-fold higher risk for HBV

FDA Adds Boxed Warning to Hepatitis C Drugs, Warns of Hepatitis B Reactivation Risk

Safety Announcement The U.S. Food and Drug Administration (FDA) is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for hepatitis C virus. In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death. As a result, we ar...

U.S.: Hepatitis C Treatment Panel Calls For Hepatitis B Testing

A new update to the guidelines for the treatment of hepatitis C recommends testing for the hepatitis B virus in all patients who are planning treatment with direct acting antiviral drugs. Hepatitis B (HBV) and C (HVC) are diseases caused by different viruses that can both start as acute infections but turn chronic in some people, eventually leading to life-threatening liver damage, according to the Centers for Disease Control and Prevention. While there a

Japan’s PMDA reviews hep B risk link to hep C therapies

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) is reviewing approved hepatitis C drugs in the country for links to a possible reactivation of the hepatitis B virus, which could result in label changes. In a notice last week, PMDA said that the review covers Gilead Sciences' ($GILD) Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) as well as AbbVie's ($ABBV) Viekirax (ombitasvir and paritaprevir and ritonavir), Bristol-Myers Squibb...